Hite Biological's 2026 interim report shows net loss widening to 78.71 million yuan

Earnings
โดย Jiemian·Read original
Summary · why it matters

Hite Biological released its 2026 interim report, with net profit attributable to the parent company at minus 78.71 million yuan, a loss expansion of 39.53 million yuan compared with the same period last year. The company's total operating revenue was 226 million yuan, down 18.01 percent year on year. Net cash outflow from operating activities was 2.87 million yuan, the asset-liability ratio rose to 15.43 percent, gross margin fell to 34.25 percent, and diluted earnings per share was minus 0.60 yuan.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews